QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: Article 31 Non-Pharmacovigilance Referrals in EU Medicines Regulation

Test your understanding of the concepts covered by Article 31 Non-Pharmacovigilance Referral in EU Medicines Regulation: Quality, Efficacy and Union-Level Regulatory Assessment.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which record structure best supports inspection readiness for an Article 31 referral?

A file containing only the final public summary A chronological record linking the initiating concern, referral, questions, responses, opinion, decision and implementation A collection of scientific publications without regulatory documents A correspondence folder organised only by employee name

Question 2 of 10 A later clinical study produces a smaller treatment effect than an earlier pivotal study. What is the most appropriate regulatory interpretation?

The product is proven ineffective The earlier study must be disregarded automatically Confidence in the efficacy conclusion may have weakened, but the integrated evidence must be assessed The matter automatically becomes a pharmacovigilance referral

Question 3 of 10 A surrogate endpoint remains statistically significant, but its relationship to patient-important outcomes is uncertain. What should the assessment address?

Only the p-value for the surrogate endpoint The endpoint's validation, magnitude of effect, clinical relevance and consistency with clinical outcomes Whether the study was conducted outside the Union Whether the MAH agrees with the statistical analysis

Question 4 of 10 Which issue is most clearly an example of a quality concern that could be relevant to a non-pharmacovigilance referral?

A signal of increased spontaneous reports of an adverse reaction A question about whether an indication remains clinically justified Evidence suggesting that a critical analytical method is not sufficiently reliable A request to harmonise adverse-reaction terminology

Question 5 of 10 Which statement correctly characterises expert consultation during a complex referral?

External experts replace CHMP's responsibility for the opinion Expert consultation can provide specialised input while CHMP remains responsible for adopting the scientific opinion Experts may redefine the legal scope without a formal procedure Expert consultation is limited to pharmacovigilance referrals

Question 6 of 10 How should a clock-stop in the referral procedure be understood?

As evidence that the procedure has been terminated As an administrative pause unrelated to the scientific assessment As a procedural period allowing the MAH or applicant to prepare responses to CHMP questions As an automatic extension of the marketing authorisation

Question 7 of 10 Which finding would most strongly suggest a systemic manufacturing-quality problem rather than an isolated batch issue?

One atypical result with a documented, controlled root cause A single laboratory deviation that cannot be reproduced Consistent failures across batches linked to a common process-control deficiency A difference between two unrelated clinical endpoints

Question 8 of 10 A Member State identifies a recurring manufacturing-control concern affecting products authorised in several Member States. Which additional consideration is central before using Article 31?

Whether the MAH agrees to the referral Whether the issue has sufficient Union-level significance and the legal conditions for referral are met Whether the product has already been suspended nationally Whether PRAC has issued a safety recommendation

Question 9 of 10 How should an MAH handle conflicting efficacy evidence in its response to CHMP?

Omit studies that do not support the company's position Address the conflicting evidence and explain differences in design, population, endpoints, follow-up or statistical power Treat the newest study as automatically decisive Conclude that the indication is invalid solely because evidence is inconsistent

Question 10 of 10 After all immediate implementation actions are completed, what is the appropriate treatment of the referral within the MAH's systems?

Delete the exceptional workstream and supporting records Close the workstream while retaining the referral in the permanent regulatory history and transferring ongoing commitments to routine lifecycle management Remove the issue from the RMP regardless of its consequences Treat the referral as closed once the CHMP opinion is published

Knowledge Assessment: Article 31 Non-Pharmacovigilance Referrals in EU Medicines Regulation

Cookie Settings